Пошук по сайту
Авторизація
Логин:
Пароль:
Регистрация
Забыли свой пароль?
Періодика
Медична інформатика та інженерія
Партнери
Поиск информации по диагнозу / Med And Me Первый украинский нефрологический сайт проф. Д. Иванова Zepter
Технічна підтримка
Ми в соц. мережах
Google+

Американські ринки пристроїв для нейростимуляції (U.S. Markets for Neurostimulation Products)




One of the most promising medical device markets to date is neurostimulation. This newest report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the United States (U.S.) neurostimulation products market. This market, as defined in this report, includes several types of implantable neurostimulation devices including cochlear implants and systems for deep brain stimulation, gastric nerve stimulation, sacral nerve stimulation, spinal cord stimulation, and vagus nerve stimulation.

Neurostimulation currently treats several debilitating conditions including chronic pain, epilepsy, essential tremor and dystonia, gastroparesis, hearing loss, incontinence, major treatment-resistant depression, obsessive-compulsive disorder, and Parkinson’s disease. Emerging and exciting areas of development include the treatment of large-population diseases and disorders including Alzheimer’s disease, blindness, chronic migraines, morbid obesity, obstructive sleep apnea, paralysis, stroke, and tinnitus, with the potential to expand to several other applications.

In addition to implantable neurostimulation systems and transcutaneous electrical nerve stimulators (TENS), this report from Medtech Insight includes analyses of transcranial magnetic nerve stimulation systems and other noninvasive electrical nerve stimulators. In addition, incidence and procedure numbers are provided for some of the most common major neurologic diseases and disorders.

The U.S. neurostimulation products market is poised for significant growth over the next decade due to factors such as the aging population, growth in age-related neurologic diseases and disorders, and the need for effective, alternative therapies. In 2009, the U.S. market for implantable neurostimulation products was estimated at $1,227.7 million; this market is expected to grow at a compound annual rate of 16.3% during the forecast period covered by this report, reaching more than $2.6 billion in the year 2014. At the same time, the market for TENS is projected to grow at a compound annual rate of 8.3%, reaching an estimated $113.8 million in the year 2014.

TABLE OF CONTENTS

Executive Summary

i. Implantable Neurostimulation Products

a. Market Analysis

ii. Transcutaneous Electrical Nerve Stimulation Products

a. Market Analysis

iii. Methodology

Exhibit ES-1: Selected Neurologic Conditions, Prevalence and Potential Neurostimulation Patient Population
Exhibit ES-2: Neurostimulation Products, Combined Market Forecast, 2009-2014
Exhibit ES-3: 2009, Neurostimulation Products Market, Estimated Percentage of Sales, by Application
Exhibit ES-4: Neurostimulation Products (Including Cochlear Implants), Market Forecast, 2009-2014
Exhibit ES-5: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2009-2014

1. OVERVIEW OF THE NERVOUS SYSTEM AND selected neurologic diseases/DISORDERS

1.1 The Nervous System
1.1.1 Sacral Nerves
1.1.2 Vagus Nerves
1.1.3 Neurons
1.1.4 Brain
1.1.5 Spine
1.2 Neurologic and Other Diseases/Disorders
1.2.1 Alzheimer’s Disease
1.2.1.1 Etiology
1.2.1.2 Incidence
1.2.1.3 Prevalence
1.2.1.4 Treatment Options
1.2.1.4.1 Drug Therapy
1.2.1.4.2 Neurostimulation and Other Device-Based Therapies
1.2.1.4.3 Surgery
1.2.1.4.4 Prevention
1.2.2 Depression
1.2.2.1 Etiology
1.2.2.2 Incidence
1.2.2.3 Prevalence
1.2.2.4 Treatment Options
1.2.2.4.1 Drug Therapy
1.2.2.4.2 Neurostimulation
1.2.2.5 Prevention
1.2.3 Epilepsy
1.2.3.1 Etiology
1.2.3.2 Incidence
1.2.3.3 Prevalence
1.2.3.4 Treatment Options
1.2.3.4.1 Drug Therapy
1.2.3.4.2 Neurostimulation
1.2.3.4.3 Surgery
1.2.3.4.4 Prevention
1.2.4 Gastroparesis
1.2.4.1 Etiology
1.2.4.2 Incidence
1.2.4.3 Prevalence
1.2.4.4 Treatment Options
1.2.4.4.1 Drug Therapy
1.2.4.4.2 Neurostimulation
1.2.4.4.3 Surgery
1.2.4.4.4 Prevention
1.2.5 Obesity
1.2.5.1 Etiology
1.2.5.2 Incidence
1.2.5.3 Prevalence
1.2.5.4 Treatment Options
1.2.5.4.1 Drug Therapy
1.2.5.4.2 Neurostimulation
1.2.5.4.3 Surgery
1.2.5.4.4 Prevention
1.2.6 Incontinence
1.2.6.1 Etiology
1.2.6.2 Incidence
1.2.6.3 Prevalence
1.2.6.4 Treatment Options
1.2.6.4.1 Drug Therapy
1.2.6.4.2 Neurostimulation
1.2.6.4.3 Surgery
1.2.6.4.4 Prevention
1.2.7 Pain
1.2.7.1 Nociceptive Pain
1.2.7.2 Neuropathic Pain
1.2.7.3 Acute Pain
1.2.7.3.1 Etiology
1.2.7.3.2 Incidence
1.2.7.3.3 Prevalence
1.2.7.3.4 Treatment Options
1.2.7.3.4.1 Neurostimulation
1.2.7.4 Chronic Pain
1.2.7.4.1 Etiology
1.2.7.4.2 Incidence
1.2.7.4.3 Prevalence
1.2.7.4.4 Treatment Options
1.2.7.4.4.1 Drug Therapy
1.2.7.4.4.2 Neurostimulation and Other Device-Based Therapies
1.2.7.4.4.3 Alternative Therapies
1.2.7.4.5 Chronic Migraine
1.2.7.4.5.1 Neurostimulation
1.2.8 Parkinson’s Disease
1.2.8.1 Etiology
1.2.8.2 Incidence
1.2.8.3 Prevalence
1.2.8.4 Treatment Options
1.2.8.4.1 Drug Therapy
1.2.8.4.2 Neurostimulation
1.2.8.4.3 Surgery
1.2.8.4.4 Prevention
1.2.9 Other Neurologic Diseases/Disorders
Exhibit 1-1: United States Population, by Age Group, Selected Years, 2000-2050
Exhibit 1-2: Selected Neurologic Conditions, Prevalence and Potential Neurostimulation Patient Population
Exhibit 1-3: The Sacral Nervous System
Exhibit 1-4: The Vagus Nerve
Exhibit 1-5: Anatomy of the Brain
Exhibit 1-6: Anatomy of the Spine
Exhibit 1-7: Alzheimer’s Disease, Facts and Figures
Exhibit 1-8: 2010, Alzheimer’s Disease Medications
Exhibit 1-9: Depression, Facts and Figures
Exhibit 1-10: Epilepsy, Facts and Figures
Exhibit 1-11: Gastroparesis, Facts and Figures
Exhibit 1-12: 2010, Obesity Comorbidities
Exhibit 1-13: Obesity, Facts and Figures
Exhibit 1-14: Urinary Incontinence, Facts and Figures
Exhibit 1-15: 2010, Treatment Options for Urinary Incontinence
Exhibit 1-16: Acute Pain, Facts and Figures
Exhibit 1-17: Chronic Pain, Facts and Figures
Exhibit 1-18: Migraine Headache, Facts and Figures
Exhibit 1-19: Parkinson’s Disease, Facts and Figures
Exhibit 1-20: Essential Tremor, Facts and Figures
Exhibit 1-21: Obsessive-Compulsive Disorder, Facts and Figures
Exhibit 1-22: Stroke, Facts and Figures
Exhibit 1-23: Obstructive Sleep Apnea, Facts and Figures
Exhibit 1-24: Tinnitus, Facts and Figures

2. NEUROSTIMULATION PRODUCTS MARKET

2.1 Implantable Neurostimulators
2.1.1 Cortical Stimulators
2.1.2 Deep Brain Stimulators
2.1.3 Gastric Nerve Stimulators
2.1.4 Sacral Nerve Stimulators
2.1.5 Spinal Cord Stimulators
2.1.6 Vagus Nerve Stimulators
2.1.7 Cochlear Implants
2.1.8 Hypoglossal Nerve Stimulators
2.1.9 Phrenic Nerve Stimulators
2.2 Core Treatment Areas for Implantable Neurostimulators
2.2.1 Major Depression
2.2.1.1 Cyberonics
2.2.1.2 Medtronic
2.2.1.3 Northstar Neuroscience
2.2.1.4 St. Jude Medical
2.2.2 Epilepsy
2.2.2.1 Cyberonics
2.2.2.2 Integra LifeSciences
2.2.2.3 Medtronic
2.2.2.4 NeuroPace
2.2.2.5 NeuroVista
2.2.2.6 Victhom Human Bionics
2.2.3 Gastroparesis
2.2.3.1 Medtronic
2.2.4 Hearing Loss
2.2.4.1 Advanced Bionics/Sonova Holding
2.2.4.2 Cochlear
2.2.4.3 MED-EL
2.2.5 Incontinence
2.2.5.1 Medtronic
2.2.6 Pain
2.2.6.1 Boston Scientific
2.2.6.2 Medtronic
2.2.6.3 MicroTransponder
2.2.6.4 St. Jude Medical
2.2.7 Dystonia, Essential Tremor, and Parkinson’s Disease
2.2.7.1 Medtrode
2.2.7.2 Medtronic
2.2.7.3 NeuroMEDx
2.2.7.4 St. Jude Medical
2.2.8 Sleep Apnea
2.2.8.1 Apnex Medical
2.2.8.2 Avery Biomedical Devices
2.2.8.3 Cardiac Concepts
2.2.8.4 ImThera Medical
2.2.8.5 Inspire Medical Systems
2.2.8.6 Synapse Biomedical
2.2.8.7 Victhom Human Bionics
2.3 Emerging Applications for Neurostimulation
2.3.1 Alzheimer’s Disease
2.3.1.1 Cyberonics
2.3.2 Blindness
2.3.2.1 Second Sight Medical Products
2.3.3 Chronic Headache
2.3.3.1 Boston Scientific
2.3.3.2 Medtronic
2.3.3.3 St. Jude Medical
2.3.4 Obesity
2.3.4.1 EnteroMedics
2.3.4.2 IntraPace
2.3.4.3 Johnson & Johnson
2.3.4.4 Leptos Biomedical
2.3.4.5 Medtronic
2.3.4.6 MetaCure
2.3.5 Obsessive-Compulsive Disorder
2.3.5.1 Medtronic
2.3.6 Stroke
2.3.6.1 Cyberonics
2.3.6.2 Northstar Neuroscience
2.3.7 Paralysis/Spinal Cord Injury
2.3.7.1 The BrainGate Company
2.3.7.2 NeuroMetrix
2.3.7.3 Össur with Victhom Human Bionics
2.3.7.4 Neurostream Technologies/Otto Bock HealthCare and Victhom Human Bionics
2.3.8 Tinnitus
2.3.8.1 Silere Medical Technology
2.4 Market Forecast
2.5 Competitive Analysis

Exhibit 2-1: 2010, Selected Advantages and Disadvantages of Neurostimulation Therapy
Exhibit 2-2: 2009, Patients Who Have Received Neurostimulation Implants, by Selected Neurologic Condition
Exhibit 2-3: 2010, Established Neurostimulation Therapies and Leading Suppliers
Exhibit 2-4: Deep Brain Stimulation
Exhibit 2-5: Neurostimulation in Suppressing Epileptic Seizures; NeuroPace’s Responsive Neurostimulator Therapy
Exhibit 2-6: Neurostimulation in the Treatment of Gastroparesis, Medtronic’s Enterra
Exhibit 2-7: Cochlear’s Nucleus Freedom Implant
Exhibit 2-8: Medtronic’s InterStim Therapy System
Exhibit 2-9: Medtronic’s Neurostimulators for the Treatment of Chronic Pain
Exhibit 2-10: St. Jude Medical’s Neurostimulators for the Treatment of Chronic Pain
Exhibit 2-11: Medtronic’s Activa Therapy for Parkinson’s Disease and Essential Tremor
Exhibit 2-12: 2010, Selected Current and Emerging Neurostimulation Systems
Exhibit 2-13: Second Sight Medical Products’ Intraocular Retinal Prosthesis
Exhibit 2-14: 2009, Neurostimulation Products Market, Estimated Percentage of Sales, by Application
Exhibit 2-15: Neurostimulation Products, Selected Market Drivers and Limiters
Exhibit 2-16: Neurostimulation Products (Including Cochlear Implants), Market Forecast, 2009-2014
Exhibit 2-17: Neurostimulation Products (Excluding Cochlear Implants), Market Forecast, 2009-2014
Exhibit 2-18: Cochlear Implants, Market Forecast, 2009-2014
Exhibit 2-19: 2009, Neurostimulation Products Market (Including Cochlear Implants), Share by Supplier
Exhibit 2-20: 2009, Neurostimulation Products Market (Excluding Cochlear Implants), Share by Supplier
Exhibit 2-21: 2009, Cochlear Implants Market, Share by Supplier

3. Transcutaneous electrical nerve stimulation products market

3.1 Overview
3.1.1 Products
3.1.1.1 American Imex
3.1.1.2 BioMedical Life Systems
3.1.1.3 Dynatronics
3.1.1.4 Empi/DJO
3.1.1.5 Neuro Resource Group
3.1.1.6 RS Medical
3.1.1.7 Zynex Medical
3.1.2 Market Analysis
3.1.3 Competitive Analysis
3.2 Other Noninvasive Electrical Stimulation Technologies
3.2.1 Transcranial Magnetic Stimulation/Other Magnetic Stimulation
3.2.1.1 Neuralieve
3.2.1.2 The Magstim Company
3.2.1.3 Neotonus
3.2.1.4 Neuronetics
3.2.1.5 Nexstim
3.2.2 Electrotherapy Technologies
3.2.2.1 Innovative Neurotronics/Hanger Orthopedic Group
3.2.2.2 Moeller Medical
3.2.2.3 Zynex Medical
Exhibit 3-1: 2010, Selected Conditions That May Be Treated Using Transcutaneous Electrical Nerve Stimulation
Exhibit 3-2: Dynatronics’ Sympathetic Therapy Systems
Exhibit 3-3: Zynex Medical’s Transcutaneous Electrical Nerve Stimulation Systems
Exhibit 3-4: 2010, Selected Transcutaneous Electrical Nerve Stimulation Devices
Exhibit 3-5: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2009-2014
Exhibit 3-6: 2009, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
Exhibit 3-7: 2010, Selected Transcranial and Other Magnetic Stimulation Systems
Exhibit 3-8: Innovative Neurotronics’ WalkAide

4. Company Profiles

4.1 Advanced Bionics Corporation/Sonova Holding AG
4.2 Apnex Medical, Inc.
4.3 BioMedical Life Systems, Inc.
4.4 Boston Scientific Corporation
4.5 Cochlear LTD
4.6 Cyberonics, Inc.
4.7 DJO, Inc.
4.8 Dynatronics Corporation
4.9 EnteroMedics, Inc.
4.10 MED-EL Corporation
4.11 Medtronic, Inc.
4.12 RS Medical, Inc.
4.13 Second Sight Medical Products, Inc.
4.14 St. Jude Medical, Inc.
Publisher: Medtech Insight
Перекладач: translate.google.com
Новини
20.11.2017  Новий тест дозволить визначити ймовірність передчасних пологів
20.11.2017  Вчені знайшли нові гени, пов'язані з інтелектуальними порушеннями
20.11.2017  Неврологи дізналися, чому позіхання настільки заразливе
20.11.2017  Новий препарат здатний перемогти рак грудей
20.11.2017  Суперкомп'ютер - розпізнати пацієнтів-симулянтів тепер простіше простого
19.11.2017  Кориця обертає назад негативні наслідки дієти з високим вмістом жирів
19.11.2017  Фахівці радять літнім людям їсти авокадо
19.11.2017  Танці - ідеальна форма фізичної активності для людей похилого віку
19.11.2017  Цукор прирівняли до повноцінних наркотичних речовин
19.11.2017  Психологи: алкоголізм при правильному підході піддається контролю
18.11.2017  Пігулка замість тренування - це реальність, за словами співробітників Університету Лідса
18.11.2017  Волоські горіхи - ключ до боротьби з переїданням, показав аналіз
18.11.2017  Безпечні харчові добавки здатні зупинити розвиток сліпоти
18.11.2017  Інтенсивні інтервальні тренування збільшують мозковий потенціал дитини
18.11.2017  Якість сну прямо пов'язана з ризиком розвитку деменції, кажуть вчені
17.11.2017  Фахівці зрозуміли, як перемогти хворобу Альцгеймера
17.11.2017  Ліки від астми знижують ризик хвороби Паркінсона
17.11.2017  Біологи розповіли, як космічні польоти відображаються на тілі космонавтів
17.11.2017  Дослідники дізналися причину побічного ефекту статинів
17.11.2017  Особливий шоколад замінює гори ліків і вітамінів
HINARI
PubMed